CN Patent

CN107001275A — Nk‑1拮抗剂的晶型

Assigned to Helsinn Healthcare SA · Expires 2017-08-01 · 9y expired

What this patent protects

本发明涉及2‑(3,5‑双(三氟甲基)苯基)‑N,2‑二甲基‑N‑(6‑(4‑甲基哌嗪‑1‑基)‑4‑(邻甲苯基)吡啶‑3‑基)丙酰胺的晶型，其为可用于治疗诱发性呕吐和其它病症的NK‑1拮抗剂。

USPTO Abstract

本发明涉及2‑(3,5‑双(三氟甲基)苯基)‑N,2‑二甲基‑N‑(6‑(4‑甲基哌嗪‑1‑基)‑4‑(邻甲苯基)吡啶‑3‑基)丙酰胺的晶型，其为可用于治疗诱发性呕吐和其它病症的NK‑1拮抗剂。

Drugs covered by this patent

Patent Metadata

Patent number
CN107001275A
Jurisdiction
CN
Classification
—
Expires
2017-08-01
Drug substance claim
No
Drug product claim
No
Assignee
Helsinn Healthcare SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.